|
Solid Neoplasm
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Recently, the folate receptor alpha has emerged as an attractive theranostic target due to its overexpression in multiple solid tumors and its great functional versatility.
|
31761235 |
2020 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Programmed death ligand-1 (PD-1/PD-L1), matrix metalloproteinases (MMPs), EpCAM (Trop1) and Trop2, cancer-testis antigen MAGE-A3, epidermal growth factor receptor (EGFR), folate receptor alpha (FRα), vascular endothelial growth factor (VEGF), and galectin-3 (Gal-3) have all been implicated as crucial factors involved with tumor survival and invasion.
|
30014686 |
2020 |
|
Neurodegeneration Due To Cerebral Folate Transport Deficiency
|
0.790 |
GeneticVariation
|
phenotype |
BEFREE |
Known defects of folate transport are deficiency of the proton coupled folate transporter, associated with systemic as well as cerebral folate deficiency, and deficiency of the folate receptor alpha, leading to an isolated cerebral folate deficiency associated with intractable seizures, developmental delay and/or regression, progressive ataxia and choreoathetoid movement disorders.
|
30916789 |
2019 |
|
Neural Tube Defects
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, doubly heterozygous mouse embryos lacking one copy each of Shroom3 and Folr1 exhibit a low rate of neural tube defects and also have lower levels of activated myosin light chain and MLCK.
|
30670450 |
2019 |
|
Neural Tube Defects
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In NTDs, there was an adaptive up-regulation of folate transporters mainly reduced folate carrier (p < 0.001) and folate receptor alpha (p < 0.001).
|
30941645 |
2019 |
|
Neural Tube Defects
|
0.400 |
Biomarker
|
group |
BEFREE |
Folates and FOLR1 are established modifiers of risk for neural tube defects, and binding data indicates DTG is a partial antagonist of FOLR1.
|
31259764 |
2019 |
|
ovarian neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
New tumor markers, such as PRSS8, FOLR1, KLK6/7, GSTT1, and miRNAs, are getting ahead and are worth noting for early detection of ovarian cancer.
|
31081307 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Folate receptor alpha (αFR) is overexpressed in 90% of ovarian cancers, one of the most lethal gynecologic cancers.
|
31261167 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
New tumor markers, such as PRSS8, FOLR1, KLK6/7, GSTT1, and miRNAs, are getting ahead and are worth noting for early detection of ovarian cancer.
|
31081307 |
2019 |
|
Movement Disorders
|
0.310 |
GeneticVariation
|
group |
BEFREE |
Known defects of folate transport are deficiency of the proton coupled folate transporter, associated with systemic as well as cerebral folate deficiency, and deficiency of the folate receptor alpha, leading to an isolated cerebral folate deficiency associated with intractable seizures, developmental delay and/or regression, progressive ataxia and choreoathetoid movement disorders.
|
30916789 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer.
|
30770191 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, a combination of curcumin and paclitaxel at less concentration may be a targeting strategy for FR-targeted drug delivery providing a better therapeutic intervention of cancer.
|
30668349 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
E39, an HLA-A2-restricted, immunogenic peptide derived from the folate-binding protein (FBP), is overexpressed in multiple malignancies.
|
31274231 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Xenografts of NaAsIII‑preconditioned MCF7 cells (MCF7NaAsIII) into the mammary fat pads of nude mice produced a larger tumor volume compared to tumors from control MCF7 cells and were more refractory to TAM in association with the reduced expression of BRCA1 and ERα, CpG hypermethylation of estrogen receptor 1 (ESR1) and BRCA1, and the increased expression of FOLR1.
|
30664189 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
|
31679978 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The correlation between <sup>89</sup>Zr-M9346A tumor uptake and treatment response using IMGN853 in FRα<sup>high</sup> TNBC PDX model suggested the potential of <sup>89</sup>Zr-M9346A PET as a noninvasive tool to prescreen patients based on the in vivo PET imaging for IMGN853-targeted treatment.
|
31369274 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have demonstrated the effectiveness of FA conjugated QDs to target tumor spheroids thus confirming the crucial role of FRα receptor as a target.
|
30885845 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer.
|
30770191 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, a combination of curcumin and paclitaxel at less concentration may be a targeting strategy for FR-targeted drug delivery providing a better therapeutic intervention of cancer.
|
30668349 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mirvetuximab Soravtansine, IMGN853, is an ADC targeting the folate receptor alpha (FRα) and has demonstrated promising single agent activity and a favorable toxicity profile in FRα-positive, platinum-resistant, epithelial ovarian cancer (EOC).
|
30531606 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
New tumor markers, such as PRSS8, FOLR1, KLK6/7, GSTT1, and miRNAs, are getting ahead and are worth noting for early detection of ovarian cancer.
|
31081307 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα).
|
30635448 |
2019 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
The efficacy of targeting strategy with FA moieties was demonstrated using the augmented cellular uptake of the FA-conjugated system on overexpressed folate receptor alpha (FRα) cells (MDA-MB-468 breast cancer cell line).
|
31349522 |
2019 |
|
Malignant neoplasm of lung
|
0.060 |
Biomarker
|
disease |
BEFREE |
Folate receptor α (FRα) is a well-studied tumor biomarker highly expressed in many epithelial tumors such as breast, ovarian, and lung cancers.
|
31369274 |
2019 |
|
Epithelial ovarian cancer
|
0.060 |
Biomarker
|
disease |
BEFREE |
Mirvetuximab Soravtansine, IMGN853, is an ADC targeting the folate receptor alpha (FRα) and has demonstrated promising single agent activity and a favorable toxicity profile in FRα-positive, platinum-resistant, epithelial ovarian cancer (EOC).
|
30531606 |
2019 |